| Literature DB >> 26299943 |
Anne Chao1, Chih-Hsien Wang2, Hao-Chun You2, Nai-Kwoun Chou2, Hsi-Yu Yu2, Nai-Hsin Chi2, Shu-Chien Huang2, I-Hui Wu2, Li-Jung Tseng2, Ming-Hsien Lin2, Yih-Sharng Chen2.
Abstract
Extracorporeal membrane oxygenation (ECMO) has been repeatedly used to rescue patients with cardiopulmonary arrest. However, its clinical utility in endocrine emergencies remains unclear. Herein, we describe a case series of 12 patients presenting with refractory shock secondary to endocrine emergencies who were rescued by ECMO support. Patients were identified between 2005 and 2012 from our ECMO registry. The diagnostic distribution was as follows: pheochromocytoma crisis (n = 4), thyroid storm (n = 5), and diabetic ketoacidosis (n = 3). The initial presentation of pheochromocytoma crisis was indistinguishable from acute myocardial infarction (AMI) and frequently accompanied by paroxysmal hypertension and limb ischemia. Thyroid storm was characterized by hyperbilirubinemia and severe gastrointestinal bleeding, whereas neurological symptoms were common in diabetic ketoacidosis. The clinical outcomes of patients with endocrine emergencies were compared with those of 80 cases with AMI who received ECMO because of cardiogenic shock. The cardiac function and the general conditions showed a significantly faster recovery in patients with endocrine emergencies than in those with AMI. We conclude that ECMO support can be clinically useful in endocrine emergencies. The screening of endocrine diseases should be considered during the resuscitation of patients with refractory circulatory shock.Entities:
Mesh:
Year: 2015 PMID: 26299943 PMCID: PMC4547135 DOI: 10.1038/srep13361
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Flow diagram of patients with endocrine emergencies who were rescued by extracorporeal membrane oxygenation.
Abbreviations: ARDS: acute respiratory distress syndrome; AMI: acute myocardial infarction; CMP: cardiomyopathy; DK: diabetic ketoacidosis; ECMO: extracorporeal membrane oxygenation; PCS: post-cardiotomy shock; PE: pulmonary embolism; PC: pheochromocytoma crisis; PHT: pulmonary hypertension; TS: thyroid storm; Tx: lung transplantation; VA: veno-arterial; VV: veno-venous.
Demographic and clinical characteristics of patients with endocrine emergencies who were rescued by extracorporeal membrane oxygenation.
| Pheochromocytoma crisis | Urine VMA/Dopa/Epi/NE | |||||||
| PC1 | 25 | F | Dyspnea, palpitations, cold sweats | Myocarditis | AMI/myocarditis | 28 | 15.3/18/51/28.3 | Yes |
| PC2 | 52 | M | Chest pain | Hypertension | AMI | 6 | 20.7/217/146/858 | Yes |
| PC3 | 40 | M | Chest pain | Hypertension | AMI | 3 | 64.3/498.3/3.34/216.2 | Yes |
| PC4 | 65 | M | Chest pain, palpitations | HBV carrier | AMI | 4 | 11/278.7/9/120.8 | Yes |
| Diabetic ketoacidosis | Blood glucose/ketone bodies | |||||||
| DK1 | 16 | F | Fever, loss of consciousness | T1DM | Septic shock | 1 | 770/+ | No |
| DK2 | 34 | M | Fever, drowsiness | Nil | Septic shock | 1 | 1505/5.9 | No |
| DK3 | 28 | F | Loss of consciousness | T1DM | DK | 1 | 994/3.6 | Yes |
| Thyroid storm | Free T4/T3/TSH | |||||||
| TS1 | 47 | M | Palpitations, exertional dyspnea | Gout | AMI | 3 | 4.26/92.7/0.04 | No |
| TS2 | 43 | M | Dyspnea | Graves’ disease, alcohol liver | Thyroid storm/CHF | 4 | 2.42/237/0.03 | No |
| TS3 | 37 | F | Dry cough, night sweating, alteration of consciousness | Graves’ disease | CHF | 1 | 7.5/-/0.03 | Yes |
| TS4 | 42 | M | Palpitations, dyspnea, nausea, delirium | Graves’ ophthalmopathy | Thyroid storm | 1 | 24/7.22/<0.01 | Yes |
| TS5 | 33 | F | Fever, shortness of breath | Hyperthyroidism | Thyroid storm | 1 | 4.5/425/<0.01 | Yes |
Abbreviations: M: male; F: female; y: years; HBV: hepatitis B virus; AMI: acute myocardial infarction; T1DM: type 1 diabetes mellitus; CHF: congestive heart failure; Dopa: dopamine (normal range: 50–450 μg·day−1); Epi: epinephrine (normal range <22.4 μg·day−1); NE: norepinephrine (normal range 12.1–85.5 μg·day−1); free T4: thyroxine (normal range: 0.89–1.76 ng/dL); T3: triiodothyronine (normal range 84–172 ng/dL); TSH: thyroid-stimulating hormone (normal range 0.4–4 μIU/mL); VMA: vanillomandelic acid (normal range 1–7 mg·day−1).
Clinical characteristics of patients with endocrine emergencies at the time of ECMO implantation.
| SOFA score (range) | 13. (9–18) | 13.7 (8–17) | 15 (13–18) |
| Extracorporeal cardiopulmonary resuscitation, n | 3 | 2 | 3 |
| Inotropic index, μg/kg/min | 28.3 | 56.8 | 35.5 |
| IABP, n | 2 | 1 | 2 |
| pH (range) | 7.30 (7.1–7.36) | 7.12 (6.63–7.39) | 7.24 (7.14–7.39) |
| Blood lactate, mmol/L (range) | 10.3 (8.7–11) | 6.25 (5.0–7.5) | 9.6 (3.5–12) |
| Initial CK, U/L (range) | 1572.5 (501–3796) | 225.3 (348–2576) | 714.3 (259–1574) |
| Initial CK-MB, U/L (range) | 86.2 (15–290) | 21.1 (14–32) | 42.6 (21–75) |
| Initial troponin-I, μg/L (range) | 37.0 (0.9–79) | 0.58 (0.5–0.7) | 0.35 (0.02–1.1) |
| Serum sodium, mEq/L (range) | 141.3 (138–144) | 146.3 (131–155) | 143 (128–149) |
| Serum BUN, mg/dL (range) | 16.9 (14–24.9) | 47.1 (37.5–52.4) | 29.4 (19.6–75.5) |
| Serum creatinine, mg/dL (range) | 2.1 (0.8–2.8) | 2.3 (2.1–2.6) | 1.6 (1.1–2.40) |
| Serum bilirubin, mg/dL (range) | 0.9 (0.4–1.40) | 0.67 (0.12–1.5) | 7.2 (2.6–14.50) |
| Serum AST, U/L (range) | 643.5 (52–2183) | 109 (15–239) | 2464.5 (195–6195) |
| Serum ALT, U/L (range) | 657.2 (47–2183) | 43 (10–73) | 761 (44–2267) |
Abbreviations: AST: aspartate aminotransferase; ALT: alanine aminotransferase; BUN: blood urea nitrogen; CK: creatine kinase; DK: diabetic ketoacidosis; IABP: intra-aortic balloon pump; PC: pheochromocytoma crisis; SOFA: sepsis-related organ failure assessment; TS: thyroid storm.
Comparisons of patients with endocrine crisis and acute myocardial infarction rescued with ECMO support.
| Age, years (range) | 45.5 (25–65) | 26 (16–34) | 40.4 (33–47) | 53.8 (31–65) |
| Male sex, n (%) | 3 (75) | 1 (33.3) | 3 (60) | 75 (94) |
| CPR, n (%) | 3 (75) | 2 (66) | 3 (60) | 55 (68.7) |
| ECMO duration, hour (range) | 102.5 (44.7–162.5) | 134.5 (0.9–381.8) | 82 (19–115.6) | 117 (5.4–475) |
| Ventilator support, day (range) | 14 (6–22) | 17.7 (1–51) | 10 (4–26) | 17.7 (1–95) |
| ICU length of stay, day (range) | 20.8 (6–28) | 18.0 (0–51) | 11.8 (5–26) | 21.6 (1–147) |
| Initial SOFA score (range) | 13 (9–18) | 13.7 (8–17) | 15 (13–18) | 10.4 (3–18) |
| MAP Day 1, mmHg (range) | 120 (101–137) | 97 (96–99) | 84 (63–101) | 74 (30–144) |
| Day 3 (range) | 121 (91–146) | 85 (84–86) | 113 (104–126) | 76 (920–112) |
| Day 6 (range) | 130 (116–145) | 99 (99) | 114 (93–132) | 88 (61–118) |
| Pre-ECMO IE, μg/kg/min | 28.3 | 56.8 | 35.5 | 21.4 |
| IE, day 3 (range) | 4.7 (2.1–7.0) | 32.4 (32.4) | 4.6 (0–18.4) | 24.1 (0–810) |
| IE, day 6 (range) | 1.4 (0–5.4) | 11.5 (11.5) | 0 (0) | 8.2 (0–31.8) |
| Patients using inotropes at day 6, n, (%) | 1 (25) | 1 (33%) | 0 (0%) | 50 (62.5%) |
| Initial CK, U/L (range) | 1572.5 (501–3796) | 225.3 (348–2576) | 714 (259–1574) | 2413 (41–28480) |
| CK day 3 (range) | 14589 (1528–47829) | 38.5 (38.5) | 8364.5 (515–4446) | 5808.4 (77–66274) |
| CK day 6 (range) | 22637 (530–13721) | 4496 (4496) | 501 (114–888) | 3163.4 (33–36621) |
| Initial CK-MB, U/L (range) | 86.2 (15–290) | 21.1 (14–32) | 42.6 (21–75) | 172 (4.2–2319.8) |
| CK-MB day 3 (range) | 3892 (90.9–10031) | 52.2 (52.2) | 53.5 (39.6–64.6) | 132.1 (1.5–1782) |
| CK-MB day 6 (range) | 66 (15.7–207) | 26 (26) | 45.1 (40.7–49.4) | 50.4 (1.2–308.9) |
| Initial Tn-I, | 37.0 (.9–79) | 0.58 (0.5–0.7) | 0.35 (0.02–1.1) | 19 (0.01–100) |
| Tn-I day 3 (range) | 16.1 (9.4–24.4) | 0.4 (0.4) | 1.2 (0.5–1.8) | 37.7 (0.44–94) |
| Tn-I day 6 (range) | 2.2 (1.26–3.1) | Not available | Not available | 16.1 (0.31–33) |
| Lactate in 24 h, mmol/L (range) | 10.3 (8.7–11) | 6.25 (5.0–7.5) | 9.6 (3.5–12) | 8.9 (1–35) |
| Dialysis patients, n | 3 | 1 | 1 | 36 |
| IABP (at implantation) | 2 | 1 | 1 | 25 (32%) |
| Bilirubin day 3, mg/dL (range) | 1.3 (1.0–1.9) | 0.9 (0.9) | 10.6 (2.0–24.8) | 2.5 (0.4–12.2) |
| Bilirubin day 6 (range) | 1.7 (1.4–1.8) | 5.5 (5.5) | 19.5 (5.67–26.9) | 3.5 (0.6–21.3) |
| LVEF day 2, % (range) | 37.7 (30–43) | 54 (54) | 24 (20–40) | 33 (7–68) |
| LVEF day 6, % (range) | 61 (50–67) | 62 (62) | 55 (38–64) | 37.4 (18–65) |
| Weaned off ECMO, (%) | 4 (100%) | 2 (66.7%) | 4 (80%) | 56 (70%) |
| Complications | ||||
| Limb ischemia | 2 | 1 | 0 | 6 |
| Massive GI bleeding | 0 | 1 | 2 | 1 |
| Corneal erosion | 0 | 0 | 1 | 0 |
| ARDS/Pneumonia | 0 | 1 | 0 | 8 |
| Reinstitution of ECMO | 1 | 0 | 0 | 1 |
| Severe brain insult | 23 | |||
| Further intervention | ||||
| CABG, n | 0 | 0 | 0 | 26 |
| Repair VSD/wall, n | 0 | 0 | 0 | 4 |
| VAD, n | 0 | 0 | 0 | 3 |
| Heart transplantation, n | 0 | 0 | 0 | 1 |
| Adrenalectomy, n | 3 | 0 | 0 | 0 |
| Cause of mortality | ||||
| Sepsis-related MOF | 0 | 1 | 0 | 7 |
| Hepatic failure, MOF | 0 | 0 | 1 | 0 |
| Cardiogenic shock | 0 | 1 | 1 | 28 |
| Brain death | 0 | 0 | 0 | 3 |
| ARDS | 0 | 0 | 0 | 2 |
| Survival to discharge (%) | 4 (100%) | 1 (33.3%) | 3 (60%) | 40 (50%) |
| Survivors with CPC I, n (%) | 4 (100% ) | 1 (100%) | 2 (66.7%) | 32 (80%) |
Abbreviations: AMI: acute myocardial infarction; ARDS: acute respiratory distress syndrome; CABG: coronary artery bypass surgery; CK: creatine kinase; CPC: cerebral performance category; CPR: cardiac pulmonary resuscitation; DK: diabetic ketoacidosis; GI: gastrointestinal; IABP: intra-aortic balloon pumping; ICU: intensive care unit; IE: inotropic equivalents; LVEF: left ventricular ejection fraction; MAP, mean arterial pressure; MOF: multiple organ failure; PC: pheochromocytoma crisis; SOFA: sepsis-related organ failure assessment; Tn-I: troponin-I, TS: thyroid storm; VAD: ventricular assist device; VSD: ventricular septal defect.